Aeolus Pharmaceuticals, Inc.
AOLS · OTC
9/30/2016 | 9/30/2015 | 9/30/2014 | 9/30/2013 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.08 | -0.00 | 4.29 | 0.02 |
| FCF Yield | -11.01% | -7.47% | 0.96% | -9.95% |
| EV / EBITDA | -7.67 | -12.80 | -401.87 | -10.76 |
| Quality | ||||
| ROIC | -102.44% | -1,672.61% | -5.05% | -382.70% |
| Gross Margin | -38.78% | -12.79% | 27.67% | 14.46% |
| Cash Conversion Ratio | 0.87 | 0.93 | -4.04 | 0.93 |
| Growth | ||||
| Revenue 3-Year CAGR | -40.04% | -7.48% | 9.71% | -6.60% |
| Free Cash Flow Growth | -27.26% | -856.35% | 110.88% | -237.88% |
| Safety | ||||
| Net Debt / EBITDA | 0.96 | -0.35 | 18.96 | 0.32 |
| Interest Coverage | -11.48 | -1,313.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 77.98 | 0.00 | 84.00 |
| Cash Conversion Cycle | 8.72 | 24.42 | -22.24 | -24.17 |